Is Egrifta (Tesamorelin) Legal in Colorado?
HealthRX.com
Egrifta is FDA-approved, but Colorado rules are a state matter
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug (BLA 022505; approved November 10, 2010) [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Formulations / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial); the labels say they are not substitutable [2][3]
- Compounding / Tesamorelin appears in no category of FDA's bulk-substance lists for state-licensed pharmacies or outsourcing facilities [4][5]
- Sport / WADA prohibits tesamorelin at all times (S2.2.4) [6][7]
The federal status
FDA approved Egrifta on November 10, 2010 under BLA 022505 [1]. The FDA record lists Egrifta as a prescription product [1]. The current labels cover two formulations, Egrifta SV and Egrifta WR, both given by subcutaneous injection once daily [2][3].
Questions worth asking
What the approval covers, and what it does not
The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label lists these limitations: long-term cardiovascular safety has not been established; prescribers should consider the risk and benefit of continuing treatment in patients who have not had a reduction in visceral adipose tissue; it is not indicated for weight loss management because its effect on weight is neutral; and there are no data to support improved adherence to antiretroviral therapy [2]. Use in people without HIV lipodystrophy falls outside the approved indication.
The two products are dosed differently. The Egrifta SV label specifies 1.4 mg once daily injected into the abdomen, reconstituted with Sterile Water for Injection [2]. The Egrifta WR label specifies 1.28 mg once daily, reconstituted with Bacteriostatic Water for Injection, with one reconstituted vial supplying seven daily doses [3]. The WR label states the two are not substitutable [3].
Compounded tesamorelin
Tesamorelin does not appear on FDA's list of bulk drug substances that may present significant safety risks when compounded (content dated April 22, 2026) [8]. It also appears in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or its list for outsourcing facilities (updated March 21, 2025), so FDA has made no category-based statement about compounding it [4][5]. Tesamorelin is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [9][10].
Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness or quality before they are marketed [10].
Athletes: a separate prohibition
WADA names tesamorelin in S2.2.4 of its Prohibited List, among growth hormone releasing factors (GHRH and its analogues). It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [6]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [6][7]. This is an anti-doping rule rather than a drug law.
Label contraindications and warnings
The label contraindicates tesamorelin in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. The label also warns about elevated IGF-1 and about glucose intolerance or diabetes; HbA1c of 6.5% or higher developed in 5% of tesamorelin-treated patients versus 1% on placebo by week 26 [2].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Colorado?
Does tesamorelin require a prescription?
Can tesamorelin be compounded?
Is tesamorelin prohibited in sport?
What is Egrifta approved to treat?
Are Egrifta SV and Egrifta WR interchangeable?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Official web page.